Skip to main content
Erschienen in: Reactions Weekly 1/2018

01.07.2018 | Case report

Bevacizumab

Lymphoedema: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Dautruche A, et al. Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique 22: 222-228, No. 3, May 2018. Available from: URL: http://doi.org/10.1016/j.canrad.2017.10.004 - France Dautruche A, et al. Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. Cancer Radiotherapie: Journal de la Societe Francaise de Radiotherapie Oncologique 22: 222-228, No. 3, May 2018. Available from: URL: http://​doi.​org/​10.​1016/​j.​canrad.​2017.​10.​004 - France
Metadaten
Titel
Bevacizumab
Lymphoedema: case report
Publikationsdatum
01.07.2018
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2018
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-018-48736-1

Weitere Artikel der Ausgabe 1/2018

Reactions Weekly 1/2018 Zur Ausgabe

Case report

Antineoplastics

Case report

Omeprazole

Case report

Multiple drugs